Ferring 
Welcome,         Profile    Billing    Logout  
 29 Products   56 Diseases   29 Products   158 Trials   7362 News 


«12345678910111213...9596»
  • ||||||||||  Adstiladrin (nadofaragene firadenovec-vncg) / Ferring, cretostimogene grenadenorepvec (CG0070) / CG Oncology
    Review, Journal:  Integrating gene therapy into the treatment paradigm for non-muscle invasive bladder cancer. (Pubmed Central) -  Feb 2, 2025   
    Significant differences in trial design limit comparability of agents across trials, highlighting the need for critical assessment of published findings. While initial investigations were in high-risk patients who recur despite frontline therapy with Bacillus Calmette-Guerin (BCG), there is growing interest in BCG-na
  • ||||||||||  Review, Journal:  Hidradenitis Suppurativa Treatment During Pregnancy and Lactation: Navigating Challenges. (Pubmed Central) -  Jan 31, 2025   
    Conversely, while newly approved HS medications such as secukinumab and bimekizumab show promise for the general population, further research is necessary to evaluate their safety profiles in pregnant and breastfeeding individuals. The scant research available on HS in pregnant and lactating women, also shown by our systematic literature review, highlights the need for a comprehensive investigation into the safety, efficacy, and suitability of management strategies.
  • ||||||||||  Review, Journal:  Management of Anal Fistula with Crohn's Disease. (Pubmed Central) -  Jan 30, 2025   
    (certolizumab pegol), anti-interleukin-12/23 (ustekinumab), and anti-?4?7 integrin antibodies (vedolizumab) were evaluated...In addition to biologics, molecular target drugs and even regenerative medicine using mesenchymal stem cells have been introduced to further expand the treatment options for consideration by medical personnel. We herein discuss the management of PFCD by focusing on studies conducted in the United States and Europe where researchers used recommended guidelines and consensus statements to evaluate the efficacy of each medication and published their findings in peer-reviewed journals.
  • ||||||||||  Cimzia (certolizumab pegol) / Astellas, UCB
    Enrollment closed, Trial completion date, Trial primary completion date:  OTIS Cimzia Pregnancy Registry (clinicaltrials.gov) -  Jan 28, 2025   
    P=N/A,  N=925, Active, not recruiting, 
    We herein discuss the management of PFCD by focusing on studies conducted in the United States and Europe where researchers used recommended guidelines and consensus statements to evaluate the efficacy of each medication and published their findings in peer-reviewed journals. Recruiting --> Active, not recruiting | Trial completion date: Oct 2026 --> Mar 2026 | Trial primary completion date: Sep 2023 --> Jan 2026
  • ||||||||||  Cimzia (certolizumab pegol) / Astellas, UCB
    Journal:  Certolizumab pegol in severe hidradenitis suppurativa in pregnancy: A case report. (Pubmed Central) -  Jan 13, 2025   
    inhibitor that lacks the fragment crystallizable region preventing active placental transfer and could be used in pregnancy and lactation if clinically needed and is label for chronic plaque psoriasis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease. Herein, we describe a case of a 32-year-old pregnant woman with Hurley stage III hidradenitis suppurativa successfully treated with certolizumab pegol.
  • ||||||||||  Cimzia (certolizumab pegol) / Astellas, UCB
    Journal:  What is Rheumatoid factor-from screening to personalized management. (Pubmed Central) -  Jan 12, 2025   
    Meanwhile, certolizumab pegol (CZP), a TNF inhibitor without the Fc region, remains at high concentrations in the blood...When serum IgM-RF levels are high, antibody drugs with the Fc region are more likely to bind to IgM-RF and be degraded. Thus, CZP without the Fc region may be more favorable for patients with high serum RF levels.
  • ||||||||||  Interventions for ocular extraintestinal manifestations in inflammatory bowel disease: an umbrella review of systematic reviews (Poster exhibition) -  Jan 11, 2025 - Abstract #ECCOIBD2025ECCO_IBD_1671;    
    Therapeutic interventions differed: two SRs evaluated vedolizumab (Zheng, 2024; Chateau, 2019), one focused on ustekinumab (Guillo, 2021), while the others assessed different advanced therapies...Conclusion Infliximab, adalimumab, certolizumab and ustekinumab appear effective for ocular EIM...Further research with clear definitions and systematic assessments of ocular manifestations is needed. A multidisciplinary approach remains crucial.
  • ||||||||||  Spevigo (spesolimab-sbzo) / Boehringer Ingelheim, Cimzia (certolizumab pegol) / Astellas, UCB
    IL-36 signaling as a drug target in Crohn (Poster exhibition) -  Jan 11, 2025 - Abstract #ECCOIBD2025ECCO_IBD_1427;    
    Boehringer Ingelheim was given the opportunity to review this abstract as a courtesy. Boehringer Ingelheim had no role in the design, analysis or interpretation of the results in this study.
  • ||||||||||  Linzess (linaclotide) / Ironwood Pharma, AbbVie, Goofice (elobixibat) / Ipsen, Amitiza (lubiprostone) / Takeda, Mallinckrodt
    Review, Journal:  Management of Chronic Constipation: A Comprehensive Review. (Pubmed Central) -  Jan 6, 2025   
    In Japan, polyethylene glycol and lactulose can now be administered under insurance coverage...The temporary use of stimulant laxatives, suppositories, enemas, and digital evacuation is also recommended. The usefulness of biofeedback is yet to be determined.
  • ||||||||||  Cervidil (dinoprostone) / Ferring
    Journal:  Identification of promising cancer target proteins of major sesquiterpene lactones from Vernonia spp. (Pubmed Central) -  Dec 27, 2024   
    This suggested that their relative binding-free energy was similar to that of well-established ligands; including PD169316, dinoprostone, and Pu-H54...Vernolide-A, vernolide-B, and vernodalin may potentially inhibit the proliferation, survival, angiogenesis, and migration of cancer cells through their strong affinity for a variety of cancer-related molecules. Additional laboratory experimental designs; including in
  • ||||||||||  Norprolac (quinagolide) / Ferring
    Journal:  Effect of prolactin concentration during the dry period on the subsequent milk production of dairy cows. (Pubmed Central) -  Dec 26, 2024   
    In this experiment, quinagolide was used to inhibit PRL secretion during the dry period...Lowering the PRL level during short dry period restored milk production to the level normally observed after a conventional dry period, which suggests that higher PRL levels during short dry period are the cause of the lower milk production after a short dry period. Ultimately, strategies to lower blood PRL level may help the adoption of short dry period.
  • ||||||||||  Trial completion, Enrollment change:  Cumulative Pregnancy Rate With Lower and Higher Gonadotropin Dose During IVF Among Poor Responders (clinicaltrials.gov) -  Dec 13, 2024   
    P=N/A,  N=190, Completed, 
    This study identifies paradoxical IBD as a consistent positive signal across multiple IMID agents, predominantly manifesting as CD, potentially aiding in timely detection and therapeutic decision-making. Recruiting --> Completed | N=700 --> 190
  • ||||||||||  Adstiladrin (nadofaragene firadenovec-vncg) / Ferring, Keytruda (pembrolizumab) / Merck (MSD), Anktiva (nogapendekin alfa inbakicept-pmln) / ImmunityBio
    Review, Journal:  Bladder-sparing Therapy for Bacillus Calmette-Gu (Pubmed Central) -  Dec 12, 2024   
    Recruiting --> Completed | N=700 --> 190 The IBCG consensus recommendations provide practical guidance on BST for BCG-U NMIBC.
  • ||||||||||  Rebyota (fecal microbiota, live-jslm) / Ferring
    Review, Journal:  Fecal microbiota live - jslm (Rebyota (Pubmed Central) -  Dec 6, 2024   
    Addressing dysbiosis via fecal microbiota transplantation is an active and promising area of research, but studies have lacked standardization which makes outcome and safety data difficult to interpret. Rebyota
  • ||||||||||  Rekovelle (follitropin delta) / Ferring
    Trial completion date, HEOR, Real-world evidence:  Real-world Evidence on Follitropin Delta Individual Dosing (clinicaltrials.gov) -  Dec 5, 2024   
    P=N/A,  N=850, Recruiting, 
    Dose compliance with estramustine phosphate predicted biochemical recurrence in patients with very high-risk prostate cancer undergoing robot-assisted radical prostatectomy with neoadjuvant chemohormonal therapy. Trial completion date: Jun 2025 --> Dec 2025